Bicycle Therapeutics (50BA) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

50BA Analyst Ratings

Moderate Buy

3 Buy

3 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Bicycle

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

50BA Stock 12 Month Forecast

Average Price Target

€8.51

▲(153.38% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Bicycle Therapeutics in the last 3 months. The average price target is €8.51 with a high forecast of €12.16 and a low forecast of €4.34. The average price target represents a 153.38% change from the last price of €3.36.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","13":"€13","4.75":"€4.75","7.5":"€7.5","10.25":"€10.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12.16236406,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€12.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.513654842,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€8.51</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.34370145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.34</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,4.75,7.5,10.25,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.34,4.018643389230769,4.697286778461539,5.3759301676923075,6.054573556923077,6.7332169461538465,7.411860335384615,8.090503724615385,8.769147113846154,9.447790503076924,10.126433892307693,10.805077281538463,11.48372067076923,{"y":12.16236406,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.34,3.737973449384615,4.13594689876923,4.5339203481538455,4.931893797538461,5.329867246923076,5.727840696307692,6.125814145692307,6.523787595076922,6.921761044461538,7.319734493846153,7.717707943230768,8.115681392615384,{"y":8.513654842,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.34,3.4172078038461535,3.4944156076923076,3.5716234115384613,3.6488312153846154,3.726039019230769,3.803246823076923,3.880454626923077,3.957662430769231,4.034870234615385,4.112078038461538,4.189285842307693,4.2664936461538465,{"y":4.34370145,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.64,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.92,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.92,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.92,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.62,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€12.16

Average Price Target€8.51

Lowest Price Target€4.34

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gregory Renza

Truist Financial

€6.08

Hold

80.99%

Upside

Reiterated

07/31/26

Truist Financial Remains a Hold on Bicycle Therapeutics (BCYC)

Jeff Jones

Oppenheimer

€31.27→€9.56

Buy

184.41%

Upside

Reiterated

07/31/26

Bicycle Therapeutics assumed with an Outperform at OppenheimerBicycle Therapeutics assumed with an Outperform at Oppenheimer

Ami Fadia

Needham

€13.03→€12.16

Buy

261.98%

Upside

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (NASDAQ: BCYC), Alnylam Pharma (NASDAQ: ALNY) and Fortrea Holdings Inc. (NASDAQ: FTRE)

Leonid Timashev

RBC Capital

€4.34

Hold

29.28%

Upside

Reiterated

07/30/26

RBC Capital Keeps Their Hold Rating on Bicycle Therapeutics (BCYC)

Tara Bancroft

TD Cowen

―

Buy

―

Reiterated

07/30/26

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (NASDAQ: ALNY), Stryker (NYSE: SYK) and Bicycle Therapeutics (NASDAQ: BCYC)

Maxwell Skor

Morgan Stanley

€10.42

Hold

210.26%

Upside

Reiterated

05/18/26

Morgan Stanley Sticks to Its Hold Rating for Bicycle Therapeutics (BCYC)

Maury Raycroft

Jefferies

€11.29→€10.42

Buy

210.26%

Upside

Reiterated

04/30/26

Bicycle Therapeutics price target lowered to $12 from $13 at JefferiesBicycle Therapeutics price target lowered to $12 from $13 at Jefferies

Reni Benjamin

Citizens JMP

€10.42→€6.95

Buy

106.84%

Upside

Reiterated

03/18/26

Bicycle Therapeutics price target lowered to $8 from $12 at CitizensBicycle Therapeutics price target lowered to $8 from $12 at Citizens

Swayampakula Ramakanth

H.C. Wainwright

€28.67

Buy

753.23%

Upside

Reiterated

10/31/25

Buy Rating for Bicycle Therapeutics: Strong Upside Potential Amid Clinical and Financial Developments

Peter Lawson

Barclays

€13.03

Buy

287.83%

Upside

Reiterated

10/31/25

Barclays Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)

Jonathan Chang

Leerink Partners

€20.85

Buy

520.53%

Upside

Reiterated

08/11/25

Leerink Partners Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gregory Renza

Truist Financial

€6.08

Hold

80.99%

Upside

Reiterated

07/31/26

Truist Financial Remains a Hold on Bicycle Therapeutics (BCYC)

Jeff Jones

Oppenheimer

€31.27→€9.56

Buy

184.41%

Upside

Reiterated

07/31/26

Bicycle Therapeutics assumed with an Outperform at OppenheimerBicycle Therapeutics assumed with an Outperform at Oppenheimer

Ami Fadia

Needham

€13.03→€12.16

Buy

261.98%

Upside

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (NASDAQ: BCYC), Alnylam Pharma (NASDAQ: ALNY) and Fortrea Holdings Inc. (NASDAQ: FTRE)

Leonid Timashev

RBC Capital

€4.34

Hold

29.28%

Upside

Reiterated

07/30/26

RBC Capital Keeps Their Hold Rating on Bicycle Therapeutics (BCYC)

Tara Bancroft

TD Cowen

―

Buy

―

Reiterated

07/30/26

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (NASDAQ: ALNY), Stryker (NYSE: SYK) and Bicycle Therapeutics (NASDAQ: BCYC)

Maxwell Skor

Morgan Stanley

€10.42

Hold

210.26%

Upside

Reiterated

05/18/26

Morgan Stanley Sticks to Its Hold Rating for Bicycle Therapeutics (BCYC)

Maury Raycroft

Jefferies

€11.29→€10.42

Buy

210.26%

Upside

Reiterated

04/30/26

Bicycle Therapeutics price target lowered to $12 from $13 at JefferiesBicycle Therapeutics price target lowered to $12 from $13 at Jefferies

Reni Benjamin

Citizens JMP

€10.42→€6.95

Buy

106.84%

Upside

Reiterated

03/18/26

Bicycle Therapeutics price target lowered to $8 from $12 at CitizensBicycle Therapeutics price target lowered to $8 from $12 at Citizens

Swayampakula Ramakanth

H.C. Wainwright

€28.67

Buy

753.23%

Upside

Reiterated

10/31/25

Buy Rating for Bicycle Therapeutics: Strong Upside Potential Amid Clinical and Financial Developments

Peter Lawson

Barclays

€13.03

Buy

287.83%

Upside

Reiterated

10/31/25

Barclays Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)

Jonathan Chang

Leerink Partners

€20.85

Buy

520.53%

Upside

Reiterated

08/11/25

Leerink Partners Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

ZURAZura Bio

TNYATenaya Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bicycle Therapeutics

3 Months

Reni BenjaminCitizens JMP

Success Rate

13/34 ratings generated profit

Average Return

-5.05%

Copying Reni Benjamin's trades and holding each position for 3 Months would result in 38.24% of your transactions generating a profit, with an average return of -5.05% per trade.

1 Year

Jonathan ChangLeerink Partners

Success Rate

6/24 ratings generated profit

Average Return

-28.56%

Copying Jonathan Chang's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -28.56% per trade.

2 Years

Ami FadiaNeedham

Success Rate

2/34 ratings generated profit

Average Return

-47.02%

Copying Ami Fadia's trades and holding each position for 2 Years would result in 5.88% of your transactions generating a profit, with an average return of -47.02% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

50BA Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 50BA has received 3 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 50BA average Analyst price target in the past 3 months is 8.51.

Each month's total comprises the sum of three months' worth of ratings.

50BA Financial Forecast

50BA Earnings Forecast

Next quarter’s earnings estimate for 50BA is -€0.40 with a range of -€0.56 to -€0.06. The previous quarter’s EPS was -€0.62. 50BA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 45.99% of the time in the same period. In the last calendar year 50BA has Performed in-line its overall industry.

50BA Sales Forecast

Next quarter’s sales forecast for 50BA is €8.09M with a range of €550.76K to €29.59M. The previous quarter’s sales results were €546.54K. 50BA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 30.22% of the time in the same period. In the last calendar year 50BA has Performed in-line its overall industry.

50BA Stock Forecast FAQ

What is DE:50BA’s average 12-month price target, according to analysts?

Based on analyst ratings, Bicycle Therapeutics Ltd’s 12-month average price target is 8.51.

What is DE:50BA’s upside potential, based on the analysts’ average price target?

Bicycle Therapeutics Ltd has 153.38% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Bicycle Therapeutics Ltd a Buy, Sell or Hold?

Bicycle Therapeutics Ltd has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 3 hold ratings and 0 sell ratings.

What is Bicycle Therapeutics Ltd’s share price target?

The average share price target for Bicycle Therapeutics Ltd is 8.51. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €12.16 ,and the lowest forecast is €4.34. The average share price target represents 153.38% Increase from the current price of €3.36.

What do analysts say about Bicycle Therapeutics Ltd?

Bicycle Therapeutics Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of Bicycle Therapeutics Ltd?

To buy shares of DE:50BA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Bicycle Therapeutics (50BA) Stock Forecast & Price Target

50BA Analyst Ratings

50BA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bicycle Therapeutics

50BA Analyst Recommendation Trends

50BA Financial Forecast

50BA Earnings Forecast

50BA Sales Forecast

50BA Stock Forecast FAQ

Detailed List of Analyst Forecasts